{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:09:32Z","timestamp":1787627372117,"version":"build-2736575974"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Mesalazine is the first-line inflammatory bowel disease (IBD) treatment. However, it can cause fatal cardiotoxicity. We aimed to analyze the clinical characteristics of mesalazine-induced cardiotoxicity and provide evidence for clinical diagnosis, treatment, and prevention.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We collected Chinese and English literature on mesalazine-induced cardiotoxicity from 1970 to 2021 for retrospective analysis.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 52 patients (40 males and 12 females) were included, with a median age of 24.5\u00a0years (range 9\u201362) and a median onset time of 14\u00a0days (range 2\u20132880). Cardiotoxicity manifested as myocarditis, pericarditis, and cardiac pericarditis. The main clinical manifestations are chest pain (82.7%), fever (46.2%), and respiratory symptoms such as dyspnea and cough (40.4%). The levels of troponin T, creatine kinase, C-reactive protein, leukocyte count, erythrocyte sedimentation rate, and other biochemical markers were significantly increased. Cardiac imaging often suggests myocardial infarction, pericardial effusion, myocardial necrosis, and other symptoms of cardiac injury. It is essential to discontinue mesalamine immediately in patients with cardiotoxicity. Although corticosteroids are a standard treatment option, the benefits remain to be determined. Re-challenge of mesalamine should be carefully considered as cardiotoxic symptoms may reoccur.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Mesalazine may cause cardiotoxicity in patients with inflammatory bowel disease, which should be comprehensively diagnosed based on clinical manifestations, biochemical indicators, and cardiac function imaging examinations. Mesalazine should be immediately discontinued, and corticosteroids may be an effective treatment for cardiotoxicity.<\/jats:p>","DOI":"10.3389\/fphar.2022.970597","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T09:08:48Z","timestamp":1663232928000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Analysis of clinical characteristics of mesalazine-induced cardiotoxicity"],"prefix":"10.3389","volume":"13","author":[{"given":"Junyu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengfei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/s0140-6736(89)92407-0","article-title":"Cardiac hypersensitivity to 5-aminosalicylic acid","volume":"1","author":"Agnholt","year":"1989","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e007405","DOI":"10.1161\/CIRCHEARTFAILURE.120.007405","article-title":"Management of acute myocarditis and chronic inflammatory cardiomyopathy: An expert consensus document","volume":"13","author":"Ammirati","year":"2020","journal-title":"Circ. Heart Fail."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1053\/j.gastro.2015.03.001","article-title":"Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: The Toronto consensus","volume":"148","author":"Bressler","year":"2015","journal-title":"Gastroenterology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"466","DOI":"10.4212\/cjhp.v69i6.1610","article-title":"5-Aminosalicylic acid-associated myocarditis and pericarditis: A narrative review","volume":"69","author":"Brown","year":"2016","journal-title":"Can. J. Hosp. Pharm."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e000587","DOI":"10.1136\/bmjgast-2020-000587","article-title":"Recurrent myocarditis in a patient with active ulcerative colitis: A case report and review of the literature","volume":"8","author":"Caio","year":"2021","journal-title":"BMJ Open Gastroenterol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1586\/1744666X.2014.902313","article-title":"Febrile pleuropericarditis, a potentially life-threatening adverse event of balsalazide--case report and literature review of the side effects of 5-aminosalicylates","volume":"10","author":"Coman","year":"2014","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/jcpt.12586","article-title":"Pericarditis during infliximab therapy in paediatric ulcerative colitis","volume":"43","author":"Dipasquale","year":"2018","journal-title":"J. Clin. Pharm. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1056\/NEJMc1903064","article-title":"Alemtuzumab for immune-related myocarditis due to PD-1 therapy","volume":"380","author":"Esfahani","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European evidence-based consensus on the diagnosis and management of crohn's disease 2016: Part 1: Diagnosis and medical management","volume":"11","author":"Gomollon","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/BF02282352","article-title":"Pleuropericarditis related to the use of mesalamine","volume":"41","author":"Gujral","year":"1996","journal-title":"Dig. Dis. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: Current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e3978","DOI":"10.7759\/cureus.3978","article-title":"Mesalamine-induced myocarditis in a young athlete: Can He run again?","volume":"11","author":"Ibrahim","year":"2019","journal-title":"Cureus"},{"key":"B13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/CJI.0000000000000239","article-title":"Autoimmune myocarditis caused by immune checkpoint inhibitors treated with antithymocyte globulin","volume":"41","author":"Jain","year":"2018","journal-title":"J. Immunother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"E1333","DOI":"10.21037\/jtd.2016.10.60","article-title":"Myocarditis with very high troponins: Risk stratification by cardiac magnetic resonance","volume":"8","author":"Janardhanan","year":"2016","journal-title":"J. Thorac. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/00005176-199710000-00015","article-title":"Massive pericardial effusion in a child following the administration of mesalamine","volume":"25","author":"Kaiser","year":"1997","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1124\/mol.105.020578","article-title":"A molecular mechanism for the anti-inflammatory effect of taurine-conjugated 5-aminosalicylic acid in inflamed colon","volume":"69","author":"Kim","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/0140-6736(90)90387-k","article-title":"Fatal myocarditis associated with mesalazine","volume":"335","author":"Kristensen","year":"1990","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1002\/ibd.21712","article-title":"Drug development in inflammatory bowel disease: The role of the FDA","volume":"17","author":"Lahiff","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"B19","first-page":"249","article-title":"Hypersensitivity perimyocarditis after the first dose of infliximab","volume":"107","author":"Lezcano-Gort","year":"2015","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"B20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"22176","DOI":"10.1038\/s41598-020-79207-z","article-title":"Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease","volume":"10","author":"Matsumoto","year":"2020","journal-title":"Sci. Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e13331","DOI":"10.1111\/ijcp.13331","article-title":"Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system","volume":"73","author":"Meng","year":"2019","journal-title":"Int. J. Clin. Pract."},{"key":"B23","doi-asserted-by":"publisher","first-page":"930190","DOI":"10.4061\/2010\/930190","article-title":"Mesalamine-induced myocarditis","volume":"2010","author":"Merceron","year":"2010","journal-title":"Cardiol. Res. Pract."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/0002-9149(84)90089-4","article-title":"Echocardiography in acute infectious myocarditis: Relation to clinical and electrocardiographic findings","volume":"53","author":"Nieminen","year":"1984","journal-title":"Am. J. Cardiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"512","DOI":"10.5009\/gnl.2012.6.4.512","article-title":"A case of acute myocarditis as the initial presentation of Crohn's disease","volume":"6","author":"Oh","year":"2012","journal-title":"Gut Liver"},{"key":"B26","doi-asserted-by":"publisher","first-page":"9813893","DOI":"10.1155\/2018\/9813893","article-title":"Myocarditis secondary to mesalamine-induced cardiotoxicity in a patient with ulcerative colitis","volume":"2018","author":"Okoro","year":"2018","journal-title":"Case Rep. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"524364","DOI":"10.1155\/2011\/524364","article-title":"Mesalamine-induced myocarditis and coronary vasculitis in a pediatric ulcerative colitis patient: A case report","volume":"2011","author":"Perez-Colon","year":"2011","journal-title":"Case Rep. Pediatr."},{"key":"B28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13256-017-1557-z","article-title":"Mesalazine-induced myocarditis: A case report","volume":"12","author":"Radhakrishnan","year":"2018","journal-title":"J. Med. Case Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1053\/j.gastro.2021.07.042","article-title":"Extraintestinal manifestations of inflammatory bowel disease: Current concepts, treatment, and implications for disease management","volume":"161","author":"Rogler","year":"2021","journal-title":"Gastroenterology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/1091581820918163","article-title":"Mesalazine induces oxidative stress and cytochrome c release in isolated rat heart mitochondria: An analysis of cardiotoxic effects","volume":"39","author":"Salimi","year":"2020","journal-title":"Int. J. Toxicol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/00005176-199809000-00015","article-title":"Recurrent pericarditis due to mesalamine hypersensitivity: A pediatric case report and review of the literature","volume":"27","author":"Sentongo","year":"1998","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"B32","doi-asserted-by":"publisher","first-page":"ytaa508","DOI":"10.1093\/ehjcr\/ytaa508","article-title":"Mesalazine-induced myopericarditis: A case report","volume":"5","author":"Shergill","year":"2021","journal-title":"Eur. Heart J. Case Rep."},{"key":"B33","first-page":"442","article-title":"Myocarditis and inflammatory bowel disease. A 16-year Danish nationwide cohort study","volume":"44","author":"Sorensen","year":"1997","journal-title":"Dan. Med. Bull."},{"key":"B34","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.rec.2015.11.011","article-title":"Cardiovascular magnetic resonance in cardiology practice: A concise guide to image acquisition and clinical interpretation","volume":"69","author":"Valbuena-Lopez","year":"2016","journal-title":"Rev. Esp. Cardiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1592\/phco.22.5.391.33188","article-title":"Possible mesalamine-induced pericarditis: Case report and literature review","volume":"22","author":"Waite","year":"2002","journal-title":"Pharmacotherapy"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.970597\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T09:09:09Z","timestamp":1663232949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.970597\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,15]]},"references-count":35,"alternative-id":["10.3389\/fphar.2022.970597"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.970597","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,15]]},"article-number":"970597"}}